To include your compound in the COVID-19 Resource Center, submit it here.

Trisenox arsenic trioxide: Phase II; marketed to treat refractory acute promyelocytic leukemia (APL)

In an ongoing U.S. Phase II in 24 patients, 33% (8/24) had 25%-50% reduction in M protein

Read the full 173 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE